



US009744209B2

(12) **United States Patent**  
**Kenney et al.**(10) **Patent No.:** **US 9,744,209 B2**  
(45) **Date of Patent:** **\*Aug. 29, 2017**(54) **VASOPRESSIN FORMULATIONS FOR USE  
IN TREATMENT OF HYPOTENSION**(71) Applicant: **Par Pharmaceutical, Inc.**, Chestnut  
Ridge, NY (US)(72) Inventors: **Matthew Kenney**, New Haven, MI  
(US); **Vinayagam Kannan**, Rochester,  
MI (US); **Sunil Vandse**, Basking Ridge,  
NJ (US); **Suketu Sanghvi**, Kendall  
Park, NJ (US)(73) Assignee: **PAR PHARMACEUTICAL, INC.**,  
Chestnut Ridge, NY (US)(\*) Notice: Subject to any disclaimer, the term of this  
patent is extended or adjusted under 35  
U.S.C. 154(b) by 0 days.This patent is subject to a terminal dis-  
claimer.(21) Appl. No.: **15/426,693**(22) Filed: **Feb. 7, 2017**(65) **Prior Publication Data**

US 2017/0157202 A1 Jun. 8, 2017

**Related U.S. Application Data**(63) Continuation-in-part of application No. 15/289,640,  
filed on Oct. 10, 2016, which is a continuation-in-part  
of application No. 14/717,877, filed on May 20, 2015,  
which is a continuation of application No.  
14/610,499, filed on Jan. 30, 2015, now abandoned.(51) **Int. Cl.****A61K 38/11** (2006.01)**A61K 47/12** (2006.01)**G01N 30/74** (2006.01)**G01N 30/88** (2006.01)**G01N 30/02** (2006.01)(52) **U.S. Cl.**CPC ..... **A61K 38/11** (2013.01); **A61K 47/12**  
(2013.01); **G01N 30/74** (2013.01); **G01N**  
**30/88** (2013.01); **G01N 2030/027** (2013.01);  
**G01N 2030/8831** (2013.01)(58) **Field of Classification Search**CPC ..... **A61K 38/11**; **C07K 7/16**  
See application file for complete search history.(56) **References Cited****U.S. PATENT DOCUMENTS**4,542,124 A 9/1985 Huffman et al.  
4,604,378 A 8/1986 Callahan et al.  
4,684,622 A 8/1987 Ali et al.  
4,746,508 A 5/1988 Carey et al.  
4,762,820 A 8/1988 Gavras  
4,764,378 A 8/1988 Keith et al.  
4,781,871 A 11/1988 West, III et al.  
5,042,975 A 8/1991 Chien et al.  
5,124,315 A 6/1992 Ceschel et al.  
5,192,741 A 3/1993 Orsolini et al.  
5,204,112 A 4/1993 Hope et al.5,225,212 A 7/1993 Martin et al.  
5,250,022 A 10/1993 Chien et al.  
5,252,263 A 10/1993 Hope et al.  
5,288,497 A 2/1994 Stanley et al.  
5,288,498 A 2/1994 Stanley et al.  
5,359,030 A 10/1994 Ekwuribe  
5,424,068 A 6/1995 Filip  
5,482,931 A 1/1996 Harris et al.  
5,698,516 A 12/1997 Nilsson et al.  
5,702,717 A 12/1997 Cha et al.  
5,770,559 A 6/1998 Manning et al.  
5,776,885 A 7/1998 Orsolini et al.  
5,785,989 A 7/1998 Stanley et al.  
5,811,399 A 9/1998 Khavinson et al.  
5,889,110 A 3/1999 Hutchinson  
5,902,790 A 5/1999 Green et al.  
5,972,894 A 10/1999 Sinackevich et al.  
5,981,474 A 11/1999 Manning et al.  
5,989,857 A 11/1999 Mundschenk  
6,004,573 A 12/1999 Rathi et al.  
6,034,175 A 3/2000 Hutchinson  
6,086,918 A 7/2000 Stern et al.  
6,117,949 A 9/2000 Rathi et al.  
6,143,722 A 11/2000 Melin et al.  
6,174,547 B1 1/2001 Dong et al.  
6,180,608 B1 1/2001 Geffer et al.  
6,187,756 B1 2/2001 Lee et al.  
6,201,072 B1 3/2001 Rathi et al.  
6,264,981 B1 7/2001 Zhang et al.  
6,287,588 B1 9/2001 Shih et al.  
6,589,549 B2 7/2003 Shih et al.  
6,592,894 B1 7/2003 Zarif et al.  
6,630,486 B1 10/2003 Royer  
6,720,001 B2 4/2004 Chen et al.  
6,740,333 B2 5/2004 Beckett et al.  
6,811,689 B2 11/2004 Zhang et al.  
6,814,870 B2 11/2004 Zhang et al.  
6,821,249 B2 11/2004 Casscells et al.  
6,841,617 B2 1/2005 Jeong et al.  
6,949,509 B2 9/2005 Woodrow  
6,967,028 B2 11/2005 Dulieu et al.  
6,991,798 B1 1/2006 Gschneidner et al.  
6,998,137 B2 2/2006 Shih et al.  
7,074,775 B2 7/2006 Miller et al.

(Continued)

**OTHER PUBLICATIONS**Label for Vasostrict (vasopressin injection) for intravenous use,  
downloaded from www.fda.gov on Mar. 21, 2017.\*AHFS Drug Information. Vasopressin. Pituitary. 2011; 68:28, 3261-  
3263.Alten, et al. Early initiation of arginine vasopressin infusion in  
neonates after complex cardiac surgery. *Pediatr Crit Care Med.* May  
2012;13(3):300-4. doi: 10.1097/PCC.0b013e31822f1753.

(Continued)

*Primary Examiner* — Christina Bradley(74) *Attorney, Agent, or Firm* — Wilson Sonsini Goodrich  
& Rosati

(57)

**ABSTRACT**Provided herein are peptide formulations comprising poly-  
mers as stabilizing agents. The peptide formulations can be  
more stable for prolonged periods of time at temperatures  
higher than room temperature when formulated with the  
polymers. The polymers used in the present invention can  
decrease the degradation of the constituent peptides of the  
peptide formulations.**13 Claims, 19 Drawing Sheets**